Monte Rosa Therapeutics, Inc.GLUEEarnings & Financial Report
Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted molecular glue degrader therapies. Its pipeline addresses unmet medical needs across oncology, rare genetic disorders and immunological diseases, with operations focused on advancing novel treatments for global patient populations.
Revenue
$60.6M
Gross Profit
N/A
Operating Profit
$13.0M
Net Profit
$13.4M
Gross Margin
N/A
Operating Margin
21.4%
Net Margin
22.2%
YoY Growth
N/A
Monte Rosa Therapeutics, Inc. Q4 FY2024 Financial Summary
Monte Rosa Therapeutics, Inc. reported revenue of $60.6M for Q4 FY2024, with a net profit of $13.4M (up 140.4% YoY) (22.2% margin).
Key Financial Metrics
| Total Revenue | $60.6M |
|---|---|
| Net Profit | $13.4M |
| Gross Margin | N/A |
| Operating Margin | 21.4% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Monte Rosa Therapeutics, Inc. Q4 FY2024 revenue of $60.6M breaks down across 2 segments, led by Novartis License Agreement at $41.6M (68.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Novartis License Agreement | $41.6M | 68.6% |
| Other | $19.0M | 31.4% |
Monte Rosa Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Monte Rosa Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Novartis License Agreement and Other) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|
| Novartis License Agreement | — | — | $6.2M | $41.6M |
| Other | — | — | $44.0M | $19.0M |
Monte Rosa Therapeutics, Inc. Annual Revenue by Year
Monte Rosa Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2023 | $0 |
Monte Rosa Therapeutics, Inc. Quarterly Revenue & Net Profit History
Monte Rosa Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $12.8M | +38.5% | $-27.1M | -212.1% |
| Q2 FY2025 | $23.2M | +394.0% | $-12.3M | -53.0% |
| Q1 FY2025 | $84.9M | +7882.0% | $46.9M | 55.2% |
| Q4 FY2024 | $60.6M | — | $13.4M | 22.2% |
| Q4 FY2023 | $0 | — | $-33.3M | N/A |
| Q3 FY2023 | $0 | — | $-34.9M | N/A |
| Q2 FY2023 | $0 | — | $-35.2M | N/A |
| Q1 FY2023 | $0 | — | $-32.0M | N/A |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $60.6M | $84.9M | $23.2M | $12.8M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 7882.0% | 394.0% | 38.5% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $309.0M | $278.6M | $252.1M | $303.8M | $438.7M | $393.2M | $359.6M | $459.8M |
| Liabilities | $65.3M | $65.0M | $67.6M | $124.5M | $215.8M | $118.0M | $91.5M | $214.0M |
| Equity | $243.7M | $213.7M | $184.5M | $179.3M | $222.9M | $275.2M | $268.1M | $245.8M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-23.4M | $-25.3M | $-24.7M | $29.6M | $128.9M | $-45.5M | $-34.7M | $100.4M |